Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Alternative donor transplant of benign primary hematologic disorders

Bone Marrow Transplantation volume 50, pages 619–627 (2015)Cite this article

Subjects

Abstract

Hematopoietic SCT is currently the only curative therapy for a range of benign inherited and acquired primary hematologic disorders in children, including BM failure syndromes and hemoglobinopathies. The preferred HLA-matched sibling donor is available for only about 25% of such children. However, there has been substantial progress over the last four decades in the use of alternative donors for those without a matched sibling—including HLA-matched unrelated donors, HLA-haploidentical related donors and unrelated-donor umbilical cord blood—so that it is now possible to find a donor for almost every child requiring an allograft. Below, we summarize the relative merits and limitations of the different alternative donors for benign hematologic conditions, first generally, and then in relation to specific disorders, and suggest recommendations for selecting such an alternative donor.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Fuchs E, O'Donnell PV, Brunstein CG . Alternative transplant donor sources: is there any consensus? Curr Opin Oncol 2013; 25: 173–179.

    CAS  PubMed  Google Scholar 

  2. Switzer GE, Bruce JG, Myaskovsky L, DiMartini A, Shellmer D, Confer DL et al. Race and ethnicity in decisions about unrelated hematopoietic stem cell donation. Blood 2013; 121: 1469–1476.

    CAS  PubMed  PubMed Central  Google Scholar 

  3. Wagner JE, Barker JN, DeFor TE, Baker KS, Blazar BR, Eide C et al. Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood 2002; 100: 1611–1618.

    CAS  PubMed  Google Scholar 

  4. Cairo MS, Rocha V, Gluckman E, Hale G, Wagner J . Alternative allogeneic donor sources for transplantation for childhood diseases: unrelated cord blood and haploidentical family donors. Biol Blood Marrow Transplant 2008; 14: 44–53.

    PubMed  Google Scholar 

  5. Yagasaki H, Kojima S, Yabe H, Kato K, Kigasawa H, Sakamaki H et al. Acceptable HLA-mismatching in unrelated donor bone marrow transplantation for patients with acquired severe aplastic anemia. Blood 2011; 118: 3186–3190.

    CAS  PubMed  Google Scholar 

  6. Handgretinger R, Klingebiel T, Lang P, Schumm M, Neu S, Geiselhart A et al. Megadose transplantation of purified peripheral blood CD34(+) progenitor cells from HLA-mismatched parental donors in children. Bone Marrow Transplant 2001; 27: 777–783.

    CAS  PubMed  Google Scholar 

  7. Aversa F, Tabilio A, Velardi A, Cunningham I, Terenzi A, Falzetti F et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998; 339: 1186–1193.

    CAS  PubMed  Google Scholar 

  8. Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood 2006; 107: 3065–3073.

    Article  CAS  PubMed  Google Scholar 

  9. Bashey A, Solomon SR . T-cell replete haploidentical donor transplantation using post-transplant CY: an emerging standard-of-care option for patients who lack an HLA-identical sibling donor. Bone Marrow Transplant 2014; 49: 999–1008.

    CAS  PubMed  Google Scholar 

  10. Fuchs EJ, Wu J, Carter S, Brunstein CG, Costa LJ, Wingard JR et al. Phase II trial of non-myeloablative conditioning and partially HLA-mismatched (HLA-haploidentical) bone marrow transplantation (BMT) for patients with hematologic malignancies: results of Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0603. Biol Blood Marrow Transplant 2011; 17: S151.

    Google Scholar 

  11. Luznik L, Bolanos-Meade J, Zahurak M, Chen AR, Smith BD, Brodsky R et al. High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease. Blood 2010; 115: 3224–3230.

    CAS  PubMed  PubMed Central  Google Scholar 

  12. Luznik L, O'Donnell PV, Symons HJ, Chen AR, Leffell MS, Zahurak M et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008; 14: 641–650.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Munchel A, Kesserwan C, Symons HJ, Luznik L, Kasamon YL, Jones RJ et al. Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep 2011; 3: e15.

    PubMed  PubMed Central  Google Scholar 

  14. Symons H, Chen AR, Leffell MS, Zahurak M, Schultz K, Karaszkiewicz H et al. HLA-haploidentical bone marrow transplantation (BMT) for high risk hematologic malignancies using myeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Blood (ASH Meeting Abstracts) 2010; 116: 2362.

    Google Scholar 

  15. Symons HJ, Fuchs EJ . Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors. Bone Marrow Transplant 2008; 42: 365–377.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ . Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2010; 16: 533–542 (in press).

    PubMed  Google Scholar 

  17. Ottinger HD, Rebmann V, Pfeiffer KA, Beelen DW, Kremens B, Runde V et al. Positive serum crossmatch as predictor for graft failure in HLA-mismatched allogeneic blood stem cell transplantation. Transplantation 2002; 73: 1280–1285.

    PubMed  Google Scholar 

  18. Champlin RE, Horowitz MM, van Bekkum DW, Camitta BM, Elfenbein GE, Gale RP et al. Graft failure following bone marrow transplantation for severe aplastic anemia: risk factors and treatment results. Blood 1989; 73: 606–613.

    CAS  PubMed  Google Scholar 

  19. Andreani M, Manna M, Lucarelli G, Tonucci P, Agostinelli F, Ripalti M et al. Persistence of mixed chimerism in patients transplanted for the treatment of thalassemia. Blood 1996; 87: 3494–3499.

    CAS  PubMed  Google Scholar 

  20. Andreani M, Nesci S, Lucarelli G, Tonucci P, Rapa S, Angelucci E et al. Long-term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow Transplant 2000; 25: 401–404.

    Article  CAS  PubMed  Google Scholar 

  21. Kapelushnik J, Or R, Filon D, Nagler A, Cividalli G, Aker M et al. Analysis of beta-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation. Blood 1995; 86: 3241–3246.

    CAS  PubMed  Google Scholar 

  22. Lawler M, McCann SR, Marsh JC, Ljungman P, Hows J, Vandenberghe E et al. Serial chimerism analyses indicate that mixed haemopoietic chimerism influences the probability of graft rejection and disease recurrence following allogeneic stem cell transplantation (SCT) for severe aplastic anaemia (SAA): indication for routine assessment of chimerism post SCT for SAA. Br J Haematol 2009; 144: 933–945.

    CAS  PubMed  Google Scholar 

  23. Andreani M, Testi M, Battarra M, Lucarelli G . Split chimerism between nucleated and red blood cells after bone marrow transplantation for haemoglobinopathies. Chimerism 2011; 2: 21–22.

    PubMed  PubMed Central  Google Scholar 

  24. Aker M, Kapelushnik J, Pugatsch T, Naparstek E, Ben-Neria S, Yehuda O et al. Donor lymphocyte infusions to displace residual host hematopoietic cells after allogeneic bone marrow transplantation for beta-thalassemia major. J Pediatr Hematol Oncol 1998; 20: 145–148.

    CAS  PubMed  Google Scholar 

  25. Ho HK, Chiang AK, Kwong YL, Chan GC, Lau YL, Ha SY et al. Pre-emptive treatment of early unstable mixed chimerism in a Chinese thalassaemia major patient by graded peripheral blood stem cell infusions. Haematologica 2003; 88: ECR03.

    PubMed  Google Scholar 

  26. Karasu GT, Yesilipek MA, Karauzum SB, Uygun V, Manguoglu E, Kupesiz A et al. The value of donor lymphocyte infusions in thalassemia patients at imminent risk of graft rejection following stem cell transplantation. Pediatr Blood Cancer 2012; 58: 453–458.

    PubMed  Google Scholar 

  27. Li CK, Chik KW, Tsang KS, Pong H, Shing MM, Yuen PM et al. Mixed chimerism after bone marrow transplantation for thalassemia major. Haematologica 2002; 87: 781–782.

    PubMed  Google Scholar 

  28. Frugnoli I, Cappelli B, Chiesa R, Biral E, Noe A, Evangelio C et al. Escalating doses of donor lymphocytes for incipient graft rejection following SCT for thalassemia. Bone Marrow Transplant 2010; 45: 1047–1051.

    CAS  PubMed  Google Scholar 

  29. Beier R, Schulz A, Honig M, Eyrich M, Schlegel PG, Holter W et al. Long-term follow-up of children conditioned with Treosulfan: German and Austrian experience. Bone Marrow Transplant 2013; 48: 491–501.

    CAS  PubMed  Google Scholar 

  30. Bernardo ME, Piras E, Vacca A, Giorgiani G, Zecca M, Bertaina A et al. Allogeneic hematopoietic stem cell transplantation in thalassemia major: results of a reduced-toxicity conditioning regimen based on the use of treosulfan. Blood 2012; 120: 473–476.

    CAS  PubMed  Google Scholar 

  31. Greystoke B, Bonanomi S, Carr TF, Gharib M, Khalid T, Coussons M et al. Treosulfan-containing regimens achieve high rates of engraftment associated with low transplant morbidity and mortality in children with non-malignant disease and significant co-morbidities. Br J Haematol 2008; 142: 257–262.

    CAS  PubMed  Google Scholar 

  32. Hongeng S, Pakakasama S, Chuansumrit A, Sirachainan N, Kitpoka P, Udomsubpayakul U et al. Outcomes of transplantation with related- and unrelated-donor stem cells in children with severe thalassemia. Biol Blood Marrow Transplant 2006; 12: 683–687.

    PubMed  Google Scholar 

  33. La Nasa G, Argiolu F, Giardini C, Pession A, Fagioli F, Caocci G et al. Unrelated bone marrow transplantation for beta-thalassemia patients: the experience of the Italian Bone Marrow Transplant Group. Ann NY Acad Sci 2005; 1054: 186–195.

    PubMed  Google Scholar 

  34. La Nasa G, Caocci G, Argiolu F, Giardini C, Locatelli F, Vacca A et al. Unrelated donor stem cell transplantation in adult patients with thalassemia. Bone Marrow Transplant 2005; 36: 971–975.

    CAS  PubMed  Google Scholar 

  35. Majhail NS, Mothukuri JM, Macmillan ML, Verneris MR, Orchard PJ, Wagner JE et al. Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr Blood Cancer 2010; 54: 138–143.

    PubMed  PubMed Central  Google Scholar 

  36. Storb R, Thomas ED, Buckner CD, Clift RA, Johnson FL, Fefer A et al. Allogeneic marrow grafting for treatment of aplastic anemia. Blood 1974; 43: 157–180.

    CAS  PubMed  Google Scholar 

  37. Deeg HJ, O'Donnell M, Tolar J, Agarwal R, Harris RE, Feig SA et al. Optimization of conditioning for marrow transplantation from unrelated donors for patients with aplastic anemia after failure of immunosuppressive therapy. Blood 2006; 108: 1485–1491.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Maury S, Balere-Appert ML, Chir Z, Boiron JM, Galambrun C, Yakouben K et al. Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient. Haematologica 2007; 92: 589–596.

    PubMed  Google Scholar 

  39. Pulsipher MA, Young NS, Tolar J, Risitano AM, Deeg HJ, Anderlini P et al. Optimization of therapy for severe aplastic anemia based on clinical, biologic, and treatment response parameters: conclusions of an international working group on severe aplastic anemia convened by the Blood and Marrow Transplant Clinical Trials Network, March 2010. Biol Blood Marrow Transplant 2011; 17: 291–299.

    PubMed  Google Scholar 

  40. Tolar J, Deeg HJ, Arai S, Horwitz M, Antin JH, McCarty JM et al. Fludarabine-based conditioning for marrow transplantation from unrelated donors in severe aplastic anemia: early results of a cyclophosphamide dose deescalation study show life-threatening adverse events at predefined cyclophosphamide dose levels. Biol Blood Marrow Transplant 2012; 18: 1007–1011.

    CAS  PubMed  PubMed Central  Google Scholar 

  41. Eapen M, Le Rademacher J, Antin JH, Champlin RE, Carreras J, Fay J et al. Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. Blood 2011; 118: 2618–2621.

    CAS  PubMed  PubMed Central  Google Scholar 

  42. Kennedy-Nasser AA, Leung KS, Mahajan A, Weiss HL, Arce JA, Gottschalk S et al. Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemia. Biol Blood Marrow Transplant 2006; 12: 1277–1284.

    PubMed  Google Scholar 

  43. Tolar J, Mehta PA, Walters MC . Hematopoietic cell transplantation for nonmalignant disorders. Biol Blood Marrow Transplant 2012; 18: S166–S171.

    PubMed  Google Scholar 

  44. Viollier R, Socie G, Tichelli A, Bacigalupo A, Korthof ET, Marsh J et al. Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant 2008; 41: 45–50.

    CAS  PubMed  Google Scholar 

  45. Bacigalupo A, Brand R, Oneto R, Bruno B, Socie G, Passweg J et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy—The European Group for Blood and Marrow Transplantation experience. Semin Hematol 2000; 37: 69–80.

    CAS  PubMed  Google Scholar 

  46. Bacigalupo A, Marsh JC . Unrelated donor search and unrelated donor transplantation in the adult aplastic anaemia patient aged 18-40 years without an HLA-identical sibling and failing immunosuppression. Bone Marrow Transplant 2013; 48: 198–200.

    CAS  PubMed  Google Scholar 

  47. Kobayashi R, Yabe H, Hara J, Morimoto A, Tsuchida M, Mugishima H et al. Preceding immunosuppressive therapy with antithymocyte globulin and ciclosporin increases the incidence of graft rejection in children with aplastic anaemia who underwent allogeneic bone marrow transplantation from HLA-identical siblings. Br J Haematol 2006; 135: 693–696.

    CAS  PubMed  Google Scholar 

  48. Maury S, Balere-Appert ML, Pollichieni S, Oneto R, Yakoub-Agha I, Locatelli F et al. Outcome of patients activating an unrelated donor search for severe acquired aplastic anemia. Am J Hematol 2013; 88: 868–873.

    PubMed  Google Scholar 

  49. Chan KW, McDonald L, Lim D, Grimley MS, Grayson G, Wall DA et al. Unrelated cord blood transplantation in children with idiopathic severe aplastic anemia. Bone Marrow Transplant 2008; 42: 589–595.

    CAS  PubMed  Google Scholar 

  50. Peffault de Latour R, Purtill D, Ruggeri A, Sanz G, Michel G, Gandemer V et al. Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the European group for blood and marrow transplantation. Biol Blood Marrow Transplant 2011; 17: 78–85.

    PubMed  Google Scholar 

  51. Yamamoto H, Kato D, Uchida N, Ishiwata K, Araoka H, Takagi S et al. Successful sustained engraftment after reduced-intensity umbilical cord blood transplantation for adult patients with severe aplastic anemia. Blood 2011; 117: 3240–3242.

    CAS  PubMed  Google Scholar 

  52. Dietz AC, Orchard PJ, Baker KS, Giller RH, Savage SA, Alter BP et al. Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita. Bone Marrow Transplant 2011; 46: 98–104.

    CAS  PubMed  Google Scholar 

  53. Islam A, Rafiq S, Kirwan M, Walne A, Cavenagh J, Vulliamy T et al. Haematological recovery in dyskeratosis congenita patients treated with danazol. Br J Haematol 2013; 162: 854–856.

    CAS  PubMed  Google Scholar 

  54. Rocha V, Devergie A, Socie G, Ribaud P, Esperou H, Parquet N et al. Unusual complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 1998; 103: 243–248.

    CAS  PubMed  Google Scholar 

  55. Gadalla SM, Sales-Bonfim C, Carreras J, Alter BP, Antin JH, Ayas M et al. Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. Biol Blood Marrow Transplant 2013; 19: 1238–1243.

    PubMed  PubMed Central  Google Scholar 

  56. Ayas M, Nassar A, Hamidieh AA, Kharfan-Dabaja M, Othman TB, Elhaddad A et al. Reduced intensity conditioning is effective for hematopoietic SCT in dyskeratosis congenita-related BM failure. Bone Marrow Transplant 2013; 48: 1168–1172.

    CAS  PubMed  Google Scholar 

  57. MacMillan ML, Hughes MR, Agarwal S, Daley GQ . Cellular therapy for fanconi anemia: the past, present, and future. Biol Blood Marrow Transplant 2011; 17: S109–S114.

    PubMed  Google Scholar 

  58. MacMillan ML, Wagner JE . Haematopoeitic cell transplantation for Fanconi anaemia - when and how? Br J Haematol 2010; 149: 14–21.

    PubMed  Google Scholar 

  59. Gluckman E, Devergie A, Dutreix J . Radiosensitivity in Fanconi anaemia: application to the conditioning regimen for bone marrow transplantation. Br J Haematol 1983; 54: 431–440.

    CAS  PubMed  Google Scholar 

  60. Kapelushnik J, Or R, Slavin S, Nagler A . A fludarabine-based protocol for bone marrow transplantation in Fanconi's anemia. Bone Marrow Transplant 1997; 20: 1109–1110.

    CAS  PubMed  Google Scholar 

  61. MacMillan ML, Auerbach AD, Davies SM, Defor TE, Gillio A, Giller R et al. Haematopoietic cell transplantation in patients with Fanconi anaemia using alternate donors: results of a total body irradiation dose escalation trial. Br J Haematol 2000; 109: 121–129.

    CAS  PubMed  Google Scholar 

  62. Wagner JE, Eapen M, MacMillan ML, Harris RE, Pasquini R, Boulad F et al. Unrelated donor bone marrow transplantation for the treatment of Fanconi anemia. Blood 2007; 109: 2256–2262.

    CAS  PubMed  PubMed Central  Google Scholar 

  63. Chaudhury S, Auerbach AD, Kernan NA, Small TN, Prockop SE, Scaradavou A et al. Fludarabine-based cytoreductive regimen and T-cell-depleted grafts from alternative donors for the treatment of high-risk patients with Fanconi anaemia. Br J Haematol 2008; 140: 644–655.

    CAS  PubMed  Google Scholar 

  64. Thakar MS, Bonfim C, Sandmaier BM, O'Donnell P, Ribeiro L, Gooley T et al. Cyclophosphamide-based in vivo T-cell depletion for HLA-haploidentical transplantation in Fanconi anemia. Pediatr Hematol Oncol 2012; 29: 568–578.

    CAS  PubMed  PubMed Central  Google Scholar 

  65. Zecca M, Strocchio L, Pagliara D, Comoli P, Bertaina A, Giorgiani G et al. HLA-haploidentical T cell-depleted allogeneic hematopoietic stem cell transplantation in children with fanconi anemia. Biol Blood Marrow Transplant 2014; 20: 571–576.

    CAS  PubMed  Google Scholar 

  66. Lucarelli G, Galimberti M, Polchi P, Angelucci E, Baronciani D, Giardini C et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990; 322: 417–421.

    CAS  PubMed  Google Scholar 

  67. Gaziev J, Marziali M, Isgro A, Sodani P, Paciaroni K, Gallucci C et al. Bone marrow transplantation for thalassemia from alternative related donors: improved outcomes with a new approach. Blood 2013; 122: 2751–2756.

    CAS  PubMed  Google Scholar 

  68. Jaing TH, Chen SH, Tsai MH, Yang CP, Hung IJ, Tsay PK et al. Transplantation of unrelated donor umbilical cord blood for nonmalignant diseases: a single institution's experience with 45 patients. Biol Blood Marrow Transplant 2010; 16: 102–107.

    PubMed  Google Scholar 

  69. Jaing TH, Tan P, Rosenthal J, Chan LL, Lin HP, Tan PL et al. Unrelated cord blood transplantation (UCBT) for transfusion-dependent thalassemia – a CIBMTR audited retrospective analysis of 51 consecutive patients. Biol Blood Marrow Transplant 2008; 14: 6–7.

    Google Scholar 

  70. Lucarelli G, Isgro A, Sodani P, Gaziev J . Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med 2012; 2: a011825.

    PubMed  PubMed Central  Google Scholar 

  71. Sodani P, Isgro A, Gaziev J, Paciaroni K, Marziali M, Simone MD et al. T cell-depleted hla-haploidentical stem cell transplantation in thalassemia young patients. Pediatr Rep 2011; 3: e13.

    PubMed  PubMed Central  Google Scholar 

  72. Lucarelli G, Andreani M, Angelucci E . The cure of thalassemia by bone marrow transplantation. Blood Rev 2002; 16: 81–85.

    CAS  PubMed  Google Scholar 

  73. Andreani M, Testi M, Gaziev J, Condello R, Bontadini A, Tazzari PL et al. Quantitatively different red cell/nucleated cell chimerism in patients with long-term, persistent hematopoietic mixed chimerism after bone marrow transplantation for thalassemia major or sickle cell disease. Haematologica 2011; 96: 128–133.

    PubMed  Google Scholar 

  74. Kharbanda S, Smith AR, Hutchinson SK, McKenna DH, Ball JB, Lamb LS Jr. et al. Unrelated donor allogeneic hematopoietic stem cell transplantation for patients with hemoglobinopathies using a reduced-intensity conditioning regimen and third-party mesenchymal stromal cells. Biol Blood Marrow Transplant 2014; 20: 581–586.

    PubMed  Google Scholar 

  75. Hsieh MM, Fitzhugh CD, Tisdale JF . Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now. Blood 2011; 118: 1197–1207.

    CAS  PubMed  PubMed Central  Google Scholar 

  76. Sauter C, Rausen AR, Barker JN . Successful unrelated donor cord blood transplantation for adult sickle cell disease and Hodgkin lymphoma. Bone Marrow Transplant 2010; 45: 1252.

    CAS  PubMed  Google Scholar 

  77. Iannone R, Casella JF, Fuchs EJ, Chen AR, Jones RJ, Woolfrey A et al. Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant 2003; 9: 519–528.

    PubMed  Google Scholar 

  78. Hsieh MM, Kang EM, Fitzhugh CD, Link MB, Bolan CD, Kurlander R et al. Allogeneic hematopoietic stem-cell transplantation for sickle cell disease. N Engl J Med 2009; 361: 2309–2317.

    CAS  PubMed  PubMed Central  Google Scholar 

  79. Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron SM, Gamper CJ, Jones RJ et al. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012; 120: 4285–4291.

    CAS  PubMed  PubMed Central  Google Scholar 

  80. Walters MC, Patience M, Leisenring W, Rogers ZR, Aquino VM, Buchanan GR et al. Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia. Biol Blood Marrow Transplant 2001; 7: 665–673.

    CAS  PubMed  Google Scholar 

  81. Jacobsohn DA, Duerst R, Tse W, Kletzel M . Reduced intensity haemopoietic stem-cell transplantation for treatment of non-malignant diseases in children. Lancet 2004; 364: 156–162.

    PubMed  Google Scholar 

  82. Shenoy S, Grossman WJ, DiPersio J, Yu LC, Wilson D, Barnes YJ et al. A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders. Bone Marrow Transplant 2005; 35: 345–352.

    CAS  PubMed  Google Scholar 

  83. Law J, Cowan MJ, Dvorak CC, Musick L, Long-Boyle JR, Baxter-Lowe LA et al. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution. Biol Blood Marrow Transplant 2012; 18: 1656–1663.

    CAS  PubMed  Google Scholar 

  84. Satwani P, Jin Z, Duffy D, Morris E, Bhatia M, Garvin JH et al. Transplantation-related mortality, graft failure, and survival after reduced-toxicity conditioning and allogeneic hematopoietic stem cell transplantation in 100 consecutive pediatric recipients. Biol Blood Marrow Transplant 2013; 19: 552–561.

    PubMed  Google Scholar 

  85. Parikh SH, Mendizabal A, Benjamin CL, Komanduri KV, Antony J, Petrovic A et al. A novel reduced-intensity conditioning regimen for unrelated umbilical cord blood transplantation in children with nonmalignant diseases. Biol Blood Marrow Transplant 2014; 20: 326–336.

    PubMed  Google Scholar 

  86. Kim SY, Lee JW, Lim J, Cho BS, Eom KS, Kim YJ et al. Unrelated donor bone marrow transplants for severe aplastic anemia with conditioning using total body irradiation and cyclophosphamide. Biol Blood Marrow Transplant 2007; 13: 863–870.

    CAS  PubMed  Google Scholar 

  87. Kosaka Y, Yagasaki H, Sano K, Kobayashi R, Ayukawa H, Kaneko T et al. Prospective multicenter trial comparing repeated immunosuppressive therapy with stem-cell transplantation from an alternative donor as second-line treatment for children with severe and very severe aplastic anemia. Blood 2008; 111: 1054–1059.

    CAS  PubMed  Google Scholar 

  88. Perez-Albuerne ED, Eapen M, Klein J, Gross TJ, Lipton JM, Baker KS et al. Outcome of unrelated donor stem cell transplantation for children with severe aplastic anemia. Br J Haematol 2008; 141: 216–223.

    PubMed  PubMed Central  Google Scholar 

  89. Bacigalupo A, Socie G, Lanino E, Prete A, Locatelli F, Locasciulli A et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA Working Party. Haematologica 2010; 95: 976–982.

    CAS  PubMed  PubMed Central  Google Scholar 

  90. Kang HJ, Shin HY, Choi HS, Ahn HS . Fludarabine, cyclophosphamide plus thymoglobulin conditioning regimen for unrelated bone marrow transplantation in severe aplastic anemia. Bone Marrow Transplant 2004; 34: 939–943.

    CAS  PubMed  Google Scholar 

  91. Lee JW, Cho BS, Lee SE, Eom KS, Kim YJ, Kim HJ et al. The outcome of unrelated hematopoietic stem cell transplants with total body irradiation (800 cGy) and cyclophosphamide (120 mg/kg) in adult patients with acquired severe aplastic anemia. Biol Blood Marrow Transplant 2011; 17: 101–108.

    PubMed  Google Scholar 

  92. Marsh JC, Gupta V, Lim Z, Ho AY, Ireland RM, Hayden J et al. Alemtuzumab with fludarabine and cyclophosphamide reduces chronic graft-versus-host disease after allogeneic stem cell transplantation for acquired aplastic anemia. Blood 2011; 118: 2351–2357.

    CAS  PubMed  Google Scholar 

  93. Urban C, Benesch M, Sovinz P, Sipurzynski S, Lackner H, Muller E et al. Alternative donor HSCT in refractory acquired aplastic anemia - prevention of graft rejection and graft versus host disease by immunoablative conditioning and graft manipulation. Pediatr Transplant 2012; 16: 577–581.

    CAS  PubMed  Google Scholar 

  94. Samarasinghe S, Steward C, Hiwarkar P, Saif MA, Hough R, Webb D et al. Excellent outcome of matched unrelated donor transplantation in paediatric aplastic anaemia following failure with immunosuppressive therapy: a United Kingdom multicentre retrospective experience. Br J Haematol 2012; 157: 339–346.

    CAS  PubMed  Google Scholar 

  95. Yoshimi A, Kojima S, Taniguchi S, Hara J, Matsui T, Takahashi Y et al. Unrelated cord blood transplantation for severe aplastic anemia. Biol Blood Marrow Transplant 2008; 14: 1057–1063.

    CAS  PubMed  Google Scholar 

  96. Liu HL, Sun ZM, Geng LQ, Wang XB, Ding KY, Tang BI et al. Unrelated cord blood transplantation for newly diagnosed patients with severe acquired aplastic anemia using a reduced-intensity conditioning: high graft rejection, but good survival. Bone Marrow Transplant 2012; 47: 1186–1190.

    CAS  PubMed  Google Scholar 

  97. Im HJ, Koh KN, Choi ES, Jang S, Kwon SW, Park CJ et al. Excellentoutcome of haploidentical hematopoietic stem cell transplantation in childrenand adolescents with acquired severe aplastic anemia. Biol Blood Marrow Transplant 2013; 19: 754–759.

    PubMed  Google Scholar 

  98. Gormley NJ, Wilder J, Khuu H, Pantin J, Donohue T, Kurlander R et al. Co-infusion of allogeneic cord blood with haploidentical CD34 cells improved transplant outcome for patients with severe aplastic anemia undergoing cord blood transplantation. Blood (ASH Meeting Abstracts) 2011; 118: 654.

    Google Scholar 

  99. Stanghellini MT, Locatelli F, Ciceri F, Locasciulli A, Dufour C, Passweg J et al. Haploidentical Hematopoietic Stem Cell Transplantation is a therapeutic option in patients with refractory acquired aplastic anemia: a survey by the severe aplastic anemia working party (SAAWP) and pediatric diseases working party (PDWP) of the EU. Bone Marrow Transplant 2014; 49: S91.

    Google Scholar 

  100. Takahashi Y, Sekiya Y, Kawashima N . Hematopoeitic Stem Cell Transplantation from analternative donor for childhood aplastic anemia: HLA haploidentical familydonor vs HLA mismatched unrelated donor. Bone Marrow Transplant 2014; 49: S124.

    Google Scholar 

  101. Yabe H, Inoue H, Matsumoto M, Hamanoue S, Hiroi A, Koike T et al. Unmanipulated HLA-haploidentical bone marrow transplantation for the treatment of fatal, nonmalignant diseases in children and adolescents. Int J Hematol 2004; 80: 78–82.

    PubMed  Google Scholar 

  102. Guardiola P, Pasquini R, Dokal I, Ortega JJ, van Weel-Sipman M, Marsh JC et al. Outcome of 69 allogeneic stem cell transplantations for Fanconi anemia using HLA-matched unrelated donors: a study on behalf of the European Group for Blood and Marrow Transplantation. Blood 2000; 95: 422–429.

    CAS  PubMed  Google Scholar 

  103. Davies SM, Khan S, Wagner JE, Arthur DC, Auerbach AD, Ramsay NK et al. Unrelated donor bone marrow transplantation for Fanconi anemia. Bone Marrow Transplant 1996; 17: 43–47.

    CAS  PubMed  Google Scholar 

  104. Gluckman E, Auerbach AD, Horowitz MM, Sobocinski KA, Ash RC, Bortin MM et al. Bone marrow transplantation for Fanconi anemia. Blood 1995; 86: 2856–2862.

    CAS  PubMed  Google Scholar 

  105. Gluckman E, Rocha V, Ionescu I, Bierings M, Harris RE, Wagner J et al. Results of unrelated cord blood transplant in fanconi anemia patients: risk factor analysis for engraftment and survival. Biol Blood Marrow Transplant 2007; 13: 1073–1082.

    PubMed  Google Scholar 

  106. Lucarelli G, Gaziev J . Advances in the allogeneic transplantation for thalassemia. Blood Rev 2008; 22: 53–63.

    PubMed  Google Scholar 

  107. Ruggeri A, Eapen M, Scaravadou A, Cairo MS, Bhatia M, Kurtzberg J et al. Umbilical cord blood transplantation for children with thalassemia and sickle cell disease. Biol Blood Marrow Transplant 2011; 17: 1375–1382.

    PubMed  PubMed Central  Google Scholar 

  108. Adamkiewicz TV, Szaboics P, Haight A, Baker KS, Staba S, Kedar A et al. Unrelated cord blood transplantation in children with sickle cell disease: review of four-center experience. Pediatr Transplant 2007; 11: 641–644.

    CAS  PubMed  Google Scholar 

  109. Mazur M, Kurtzberg J, Halperin E, Ciocci G, Szabolcs P . Transplantation of a child with sickle cell anemia with an unrelated cord blood unit after reduced intensity conditioning. J Pediatr Hematol Oncol 2006; 28: 840–844.

    CAS  PubMed  Google Scholar 

  110. Kamani NR, Walters MC, Carter S, Aquino V, Brochstein JA, Chaudhury S et al. Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). Biol Blood Marrow Transplant 2012; 18: 1265–1272.

    PubMed  PubMed Central  Google Scholar 

  111. Radhakrishnan K, Bhatia M, Geyer MB, Del Toro G, Jin Z, Baker C et al. Busulfan, fludarabine, and alemtuzumab conditioning and unrelated cord blood transplantation in children with sickle cell disease. Biol Blood Marrow Transplant 2013; 19: 676–677.

    CAS  PubMed  Google Scholar 

  112. Dallas MH, Triplett B, Shook DR, Hartford C, Srinivasan A, Laver J et al. Long-term outcome and evaluation of organ function in pediatric patients undergoing haploidentical and matched related hematopoietic cell transplantation for sickle cell disease. Biol Blood Marrow Transplant 2013; 19: 820–830.

    PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

This study was supported by grants from the NCI (#1R13CA177155-01), NHLBI (#5U10HL069254-13), Pediatric Cancer Research Foundation, Children’s Cancer Fund, NMDP Foundation and St Baldrick’s Foundation.

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA

    J Tolar

  2. Department of Hematology, Tor Vergata Hospital, Rome, Italy

    P Sodani

  3. Department of Pediatrics, John Hopkins Hospital, Baltimore, MD, USA

    H Symons

Authors
  1. J Tolar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Sodani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H Symons
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to H Symons.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tolar, J., Sodani, P. & Symons, H. Alternative donor transplant of benign primary hematologic disorders. Bone Marrow Transplant 50, 619–627 (2015). https://doi.org/10.1038/bmt.2015.1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.1

This article is cited by

Search

Advanced search

Quick links